One To Watch

Cocrystal Pharma

Company Overview

A clinical-stage biotechnology company using Nobel laureate-derived co-crystal structure-based drug design to develop oral antivirals against norovirus, influenza A, and coronaviruses — targets where the approved treatment landscape remains thin or entirely absent. Cocrystal's lead asset, CDI-988, is positioned as a potential first-ever oral antiviral for norovirus, a virus that infects roughly 685 million people globally each year and has no approved treatment or vaccine. Its second clinical program, CC-42344, targets influenza A via a PB2 mechanism distinct from the standard-of-care neuraminidase inhibitors, with documented in vitro activity against Tamiflu- and Xofluza-resistant strains. The company trades on the Nasdaq Capital Market under the ticker COCP.

Headquarters and Global Presence

Cocrystal Pharma is headquartered in Bothell, Washington. Its Phase IIa influenza challenge study for CC-42344 is conducted at a single site in the United Kingdom, and its Phase Ib norovirus challenge study is being run at Emory University School of Medicine in Atlanta, Georgia.

Founding and History

The company's scientific roots trace to the structural biology work of Nobel laureate biochemist Roger D. Kornberg, Ph.D., whose near-atomic resolution crystallography underpins the platform. A significant corporate milestone arrived when Cocrystal Pharma merged with RFS Pharma, a privately held biotech founded by renowned drug developer Raymond Schinazi — a transaction that closed in June 2024 and deepened the company's antiviral portfolio. The merger added hepatitis C virus to a pipeline already covering norovirus, influenza, and coronaviruses. The company has since focused its clinical resources on CDI-988 and CC-42344.

Therapy Areas and Focus

Cocrystal's programs sit at the intersection of acute viral illness and pandemic preparedness — areas where the commercial and public-health case for new oral antivirals is clear but industry investment remains uneven. Norovirus represents the sharpest unmet need: responsible for 200,000 deaths annually, predominantly in low-income settings, it has no approved therapeutic and no licensed vaccine. Influenza A, while better served by existing drugs, still faces resistance erosion of both oseltamivir (Tamiflu) and baloxavir (Xofluza), and the emergence of H5N1 in humans exposed to infected dairy cattle has renewed pandemic-preparedness urgency. Coronaviruses and hepatitis C round out a portfolio deliberately focused on conserved viral targets susceptible to structure-guided attack.

Technology Platforms and Modalities

The company's co-crystal structure-based design platform resolves three-dimensional inhibitor-target complexes at near-atomic resolution, enabling precision engineering of small molecules against conserved viral enzyme sites. The approach matters because conserved regions — unlike the surface proteins that mutate rapidly under immune pressure — change slowly, making resistance emergence harder. CDI-988 exploits this logic against the 3CL protease, a catalytic domain that noroviruses and coronaviruses share and that cannot easily mutate without losing function. CC-42344 applies the same structural discipline to the PB2 cap-binding domain of the influenza RNA polymerase, a mechanistically distinct target from both neuraminidase inhibitors and the PA-site inhibitor baloxavir.

Key Pipeline and Programs

CDI-988 is an oral, broad-spectrum 3CL protease inhibitor targeting a conserved active site shared across noroviruses, coronaviruses, and other caliciviruses. The FDA granted CDI-988 Fast Track designation in April 2026 for the treatment and prevention of norovirus infection — a meaningful regulatory step that opens rolling NDA review and more frequent agency interaction. A Phase Ib randomized, double-blind, placebo-controlled human challenge study is underway at Emory University School of Medicine in up to 40 healthy adults, with the primary endpoint being reduction in clinical norovirus symptom incidence; secondary endpoints cover viral shedding, disease severity, safety, and pharmacokinetics. The same 3CL protease mechanism also gives CDI-988 a theoretical line of activity against SARS-CoV-2 and MERS-CoV, though norovirus is the regulatory lead indication.

CC-42344 is an oral PB2 cap-binding domain inhibitor selective for the influenza A RNA polymerase. It has demonstrated in vitro activity against seasonal H3N2, H1N1, and pandemic strains, including those carrying mutations conferring resistance to oseltamivir and baloxavir — a profile that addresses the resistance concern most likely to erode the current standard of care. A Phase IIa randomized, double-blind, placebo-controlled human challenge study enrolling 78 subjects at a UK site completed enrollment in 2024, though the company announced in December 2024 that it would extend enrollment following unexpectedly low infection rates in participants challenged with H3N2. Cocrystal has also flagged the potential relevance of CC-42344 to H5N1 strains circulating in humans with dairy-cattle exposure.

Recent Developments

The most consequential development of 2026 is the appointment on June 3 of James Sapirstein as sole CEO, replacing the co-CEO structure of Sam Lee and Jim Martin; Lee transitions to President and Chief Scientific Officer, Martin remains CFO. In April 2026, the FDA's Fast Track designation for CDI-988 in norovirus marked the program's clearest regulatory milestone to date. Financially, the company reported $4.7 million in unrestricted cash and a $2.3 million net loss for Q1 2026, with $225,000 in NIH SBIR grant revenue — a cash position that makes near-term capital deployment a live question.

Key Personnel

James Sapirstein was appointed CEO on June 3, 2026, bringing roughly 36 years of biopharma experience spanning Gilead Sciences, Bristol Myers Squibb, Serono, and executive roles at ContraVir Pharmaceuticals, Tobira Therapeutics, and most recently Entero Therapeutics; he has been involved in 23 product launches. Sam Lee serves as President and Chief Scientific Officer, having previously co-led the company as Co-CEO; his scientific background anchors the structure-based discovery platform. Jim Martin continues as Chief Financial Officer, a role he held concurrently with the Co-CEO position.

Strategic Partnerships

The merger with RFS Pharma, founded by Raymond Schinazi, brought additional antiviral intellectual property including hepatitis C assets into the Cocrystal portfolio. The company receives non-dilutive funding via NIH Small Business Innovation Research awards, which contributed $225,000 in Q1 2026 revenue. No major commercial licensing or co-development deal with a large-pharma partner has been disclosed.

FAQ Section

Norovirus infects an estimated 685 million people annually and kills around 200,000, yet no approved antiviral or licensed vaccine exists — making it a genuine white space rather than a crowded market. The 3CL protease target CDI-988 addresses is highly conserved, which reduces the mutation pressure that defeated earlier broad-spectrum attempts. The April 2026 FDA Fast Track designation signals that regulators share the view that the unmet need is real and the mechanism is credible.

The 3CL protease is an essential enzyme shared across noroviruses, coronaviruses, and related caliciviruses, and its active site is structurally conserved because mutations there typically destroy viral replication fitness. This makes it far more resistant to drug-escape evolution than surface proteins like hemagglutinin. Pfizer's Paxlovid validated the 3CL protease as a druggable class in coronaviruses; CDI-988 extends that logic to norovirus, where no approved inhibitor exists.

CC-42344 targets the PB2 cap-binding domain of the influenza A RNA polymerase, a site mechanistically distinct from the neuraminidase (Tamiflu's target) and the PA endonuclease domain (Xofluza's target). Crucially, it has shown in vitro activity against strains carrying oseltamivir- and baloxavir-resistance mutations, giving it a potential role if either standard-of-care drug loses efficacy in a seasonal or pandemic setting. Its activity profile also covers H5N1 strains, which regulators and public-health authorities are watching closely.

CDI-988 has cleared FDA IND review and entered a Phase Ib randomized, placebo-controlled human challenge study at Emory University in up to 40 healthy adults, with the primary endpoint being reduction in clinical norovirus symptom incidence. Human challenge studies compress development timelines by generating controlled efficacy signals without waiting for natural infection seasons — a practical advantage for a virus with no natural epidemiological rhythm for trial planning. A clean safety and efficacy signal here would represent the first clinical proof-of-concept for any oral norovirus antiviral.

The portfolio is built entirely around RNA virus infectious disease, targeting four pathogen families: caliciviruses (norovirus), orthomyxoviruses (influenza A), coronaviruses (SARS-CoV-2, MERS-CoV), and flaviviruses/hepaciviruses (hepatitis C, inherited from the RFS Pharma merger). The unifying logic is structure-guided inhibition of conserved viral enzymes — polymerases and proteases — rather than surface-antigen strategies that mutate rapidly. This is a deliberately focused, science-driven scope rather than a diversified therapeutic portfolio.

Cocrystal is operating at the Phase Ib and Phase IIa stages simultaneously — early enough that both programs carry substantial binary risk, but advanced enough to generate human efficacy signals within the next 12 to 18 months. The CC-42344 Phase IIa challenge study at a UK site enrolled 78 subjects but required enrollment extension in December 2024 due to low H3N2 infection rates among challenged participants; data readout timing remains contingent on achieving adequate infection rates. CDI-988's Phase Ib at Emory is the nearer-term catalyst, and Fast Track status will accelerate FDA dialogue once preliminary data emerge.

Cocrystal is at a pivotal but financially precarious juncture. The key watchpoints are:

Cash runway: $4.7 million in unrestricted cash as of March 31, 2026, against a $2.3 million quarterly burn rate — a runway that makes near-term financing or partnership activity a necessity rather than an option.
CC-42344 challenge study: enrollment extension signals difficulty achieving adequate infection rates; if the study cannot generate a clean efficacy readout, the program loses momentum precisely when H5N1 anxiety might otherwise attract attention.
CDI-988 Phase Ib data: the first human efficacy signal for a norovirus antiviral would be a genuine industry milestone and the most likely share-price catalyst.
Leadership transition: Sapirstein's appointment as sole CEO ends the co-CEO structure, potentially accelerating partnership discussions given his commercial and deal-making background.
Micro-cap liquidity: at a ~$14 million market cap, any material financing is likely to be dilutive at current prices.

Want to Update your Company's Profile?